glp type 1 diabetes SGLT2i and GLP-1 RA therapy in and reno-vascular outcomes: a real-world study | Diabetologia GLP-1 Receptor Agonists as Treatments

10.1016/S2468-1253(23)00068-7 48 LuX.XuC.DongJ.ZuoS.ZhangH.JiangC.et al (2021)

According to research, administering MK-677 daily can lead to a 55% increase in IGF-1 levels at 2 weeks and 88% at 4 weeks [12, 13]

This has created an environment where both traditional and alternative GLP-1 strategies are being evaluated side by side

Nature 471(7338):368372

*Correspondence: Shuxin Han, [email protected] This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

It does not require encapsulation, a carrier molecule, or special formulation to maintain structural integrity in biological environments